LYEL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LYEL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Lyell Immunopharma's quick ratio for the quarter that ended in Dec. 2024 was 7.06.
Lyell Immunopharma has a quick ratio of 7.06. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lyell Immunopharma's Quick Ratio or its related term are showing as below:
During the past 6 years, Lyell Immunopharma's highest Quick Ratio was 19.97. The lowest was 7.06. And the median was 14.74.
The historical data trend for Lyell Immunopharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyell Immunopharma Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Quick Ratio | Get a 7-Day Free Trial | 12.53 | 13.40 | 17.59 | 16.07 | 7.06 |
Lyell Immunopharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Quick Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
16.07 | 16.51 | 16.19 | 13.43 | 7.06 |
For the Biotechnology subindustry, Lyell Immunopharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lyell Immunopharma's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Quick Ratio (A: Dec. 2024 ) | = | (Total Current Assets | - | Total Inventories) | / | Total Current Liabilities |
= | (379.594 | - | 0) | / | 53.788 | |
= | 7.06 |
Lyell Immunopharma's Quick Ratio for the quarter that ended in Dec. 2024 is calculated as
Quick Ratio (Q: Dec. 2024 ) | = | (Total Current Assets | - | Total Inventories) | / | Total Current Liabilities |
= | (379.594 | - | 0) | / | 53.788 | |
= | 7.06 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyell Immunopharma (NAS:LYEL) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Lyell Immunopharma's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles W. Newton | officer: Chief Financial Officer | 46 FREDRICK AVENUE, ATHERTON CA 94027 |
Lynn Seely | director | 501 2ND STREET, SUITE 211, SAN FRANCISCO CA 94107 |
Richard Klausner | director, officer: Executive Chairman | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Matthew Lang | officer: Chief Business Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Rahsaan Thompson | officer: Chief Legal Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Tina M. Albertson | officer: Chief Medical Officer | C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080 |
Gary K. Lee | officer: Chief Scientific Officer | C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080 |
Cathy Friedman | director | C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005 |
Arch Venture Fund Ix Overage, L.p. | 10 percent owner | 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631 |
Elizabeth Homans | director, officer: Chief Executive Officer | C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080 |
Stephen J. Hill | officer: Chief Technical Ops. Officer | C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080 |
Otis W Brawley | director | 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518 |
Elizabeth G Nabel | director | BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115 |
William Jl Rieflin | director | NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
Arch Venture Partners Ix, Llc | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By Marketwired • 09-27-2023
By GuruFocus Research • 02-28-2024
By PRNewswire • 09-11-2023
By Marketwired • 08-07-2024
By Marketwired • 08-28-2024
By sperokesalga sperokesalga • 06-07-2023
By Marketwired • 06-03-2024
By Marketwired • 03-11-2025
By sperokesalga sperokesalga • 05-04-2023
By Marketwired • 02-18-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.